BRISTOL MYERS SQUIBB News & Analysis

All but a couple of shares in this industry have sold off. Our analysts think these three high quality companies have fallen too far. 

And what we expect to see moving forward.

Bristol-Myers Squibb Co says it will buy Celgene Corp for about $105bn, combining two of the world's largest cancer drug businesses in the biggest...